Novartis turns to algorithms developer Anumana to apply AI to cardio conditions

Related Articles
Anumana Demonstrates Global Readiness with Receipt of ISO 13485 Certification
Anumana Demonstrates Global Readiness with Receipt of ISO 13485 CertificationCAMBRIDGE, Mass. – May 21, 2024 – Anumana, a leading AI-driven health technology company and portfolio company of nference, announced today…May 21, 2024
Pfizer, Anumana team up to develop AI algorithm for cardiac amyloidosis detection
Mobi Health News: Anumana, a joint venture between EHR data company nference and the Mayo Clinic, entered into a multiyear partnership with Pfizer to develop an AI-based tool for the…December 16, 2022
Anumana Announces Issuance of New American Medical Association CPT® Category III Codes for Novel ECG AI Analysis of Cardiac Dysfunction
Ground-breaking codes will facilitate the use, adoption, and pathway for potential reimbursement of AI-enhanced ECG-based algorithms, including Anumana’s pipeline of AI- enhanced ECG-based algorithmsJuly 05, 2022
Anumana Named to Fierce Medtech’s 2022 Fierce 15
AI-driven startup from nference and Mayo Clinic Platform positioned to transform cardiac careMarch 20, 2023


